PriceTargets.com logo

PDL BioPharma - PDLI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.47 As of 01/18/2022 01:00 AM ET
+0 (0.00%)
Get New PDL BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PDLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PDLI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for PDL BioPharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.47.

This chart shows the closing price for PDLI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in PDL BioPharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/9/2019CowenReiterated RatingHold$3.00High
8/7/2019CowenSet TargetHold$3.00High
5/9/2019CowenReiterated RatingHoldMedium
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
PDL BioPharma logo
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Read More

Today's Range

Now: $2.47
Low: $2.47
High: $2.47

50 Day Range

MA: $2.47
Low: $2.47
High: $2.47

52 Week Range

Now: $2.47
Low: $2.09
High: $3.86

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of PDL BioPharma?

The following equities research analysts have issued reports on PDL BioPharma in the last year:
View the latest analyst ratings for PDLI.

What is the current price target for PDL BioPharma?

0 Wall Street analysts have set twelve-month price targets for PDL BioPharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for PDL BioPharma in the next year.
View the latest price targets for PDLI.

What is the current consensus analyst rating for PDL BioPharma?

PDL BioPharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PDLI.

What other companies compete with PDL BioPharma?

Other companies that are similar to PDL BioPharma include Genocea Biosciences, VectivBio, 180 Life Sciences, 60 Degrees Pharmaceuticals and Aclarion. Learn More about companies similar to PDL BioPharma.

How do I contact PDL BioPharma's investor relations team?

PDL BioPharma's physical mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company's listed phone number is 775-832-8500 and its investor relations email address is [email protected]. The official website for PDL BioPharma is www.pdl.com. Learn More about contacing PDL BioPharma investor relations.